Clinical significance of MLH1/MSH2 for stage II/III sporadic colorectal cancer

Table 2 Relationship between clinicopathological features and MutL homolog1/MutS homolog2 expression in 681 patients, n (%)

Observation	Positivea	Negativeb	Total	χ2	P value
Gender
Male	310 (80.10)	77 (19.90)	387	0.252	0.625
Female	240 (81.63)	54 (18.37)	294
Age (yr)
≤50	63 (88.73)	8 (11.27)	71	3.240	0.072
>50	487 (79.84)	123 (20.16)	610
Location in the colon
Left	138 (82.14)	30 (17.86)	168	4.746	0.029
Right	119 (72.12)	46 (27.88)	165
Location of tumor Colon	257 (77.18)	76 (22.82)	333	5.395	0.025
Rectum	293 (84.20)	55 (15.80)	348
Grade of differentiation
Poor	28 (66.67)	14 (33.33)	42	5.725	0.017
Well-moderate	522 (81.69)	117 (18.31)	639
Tumor stage (TNM)
II	324 (82.03)	71 (17.97)	395	0.964	0.327
III	226 (79.02)	60 (20.98)	286
Tumor size (cm)
≤4	210 (78.95)	56 (21.05)	266	0.927	0. 370
>4	340 (81.93)	75 (18.07)	415
Lymphocytic infiltration
None or little	336 (82.76)	70 (17.24)	406	1.195	0.332
Marked or moderate	214 (75.76)	61 (27.24)	275
Mucin
Positive	108 (73.97)	38 (26.03)	146	5.517	0.024
Negative	442 (82.62)	93 (17.38)	535
Circumscribed margin
Negative	482 (79.80)	122 (20.20)	604	3.184	0.090
Positive	68 (88.31)	9 (11.69)	77

^aMLH1/MSH2 positive;

^bMLH1/MSH2 negative. MLH1: MutL homolog 1; MSH2: MutS homolog 2.